Nav: Home

Nonfunctional adrenal tumors significantly increase risk for diabetes

August 01, 2016

1. Patients with "nonfunctional" adrenal tumors at significantly higher risk for diabetes
Abstract: http://www.annals.org/article.aspx?doi=10.7326/M16-0547
URL goes live when the embargo lifts

Patients with nonfunctional adrenal tumors have a significantly higher risk for diabetes compared to patients without adrenal tumors. These findings suggest that a classification of "nonfunctional" may not adequately describe the continuum of hormone secretion and metabolic risk associated with benign adrenal tumors. The study is published in Annals of Internal Medicine.

Adrenal tumors are typically benign and affect up to 10 percent of the population. While benign adrenal tumors are commonly thought to be nonfunctional, a substantial proportion may be functional in that they secrete detectable adrenocortical hormones. Known as subclinical hypercotisolism, the condition is associated with hypertension, insulin resistance, type 2 diabetes, hyperlipidemia, osteoporosis, and obesity. In recent studies, subclinical hypercotisolism was linked to an increased risk for cardiovascular events and death compared to nonfunctional adrenal tumors. Therefore, screening for hypercortisolism is recommended for all patients with adrenal tumors. However, emerging evidence suggests that nonfunctional adrenal tumors may be associated with cardiometabolic disease.

Researchers compared medical records for 166 patients with benign nonfunctional adrenal tumors to those of 740 patients with no adrenal tumor to look for development of cardiometabolic outcomes, such as hypertension, diabetes, or cardiovascular events. They found that patients with nonfunctional adrenal tumors were significantly more likely to develop diabetes than those without adrenal tumors. These findings suggest that nonfunctional adrenal tumors may warrant more clinical attention and should be considered an independent risk factor for diabetes.

Note: For an embargoed PDF, please contact Cara Graeff. To reach the lead author, Dr. Anand Vaidya, please contact Haley Bridger at hbridger@partners.org or 617-525-6383.




2. Trend report: No increase in overall prevalence of late stage chronic kidney disease over the past decade
Abstract: http://www.annals.org/article.aspx?doi=10.7326/M16-0273
Editorial: http://www.annals.org/article.aspx?doi=10.7326/M16-1649
URL goes live when the embargo lifts

In a reversal of previous trends, no increase in the prevalence of stage 3 and 4 chronic kidney disease (CKD) has been seen in the U.S. population over the most recent decade. The findings are published in Annals of Internal Medicine.

CKD is recognized as an important risk factor for end-stage renal disease, acute kidney injury, cardiovascular disease, and premature death. As such, national health programs, such as the U.S. Department of Health and Human Services' Healthy People 2020 initiative, have set a target of a 10 percent proportional reduction in CKD prevalence in the U.S. population. While peer-reviewed publications have mostly reported that the overall prevalence of CKD in the U.S. population had been increasing by as much as 5 percent per year, it has been noted that the incidence rate of end-stage renal disease, which is almost always preceded by CKD, have been decreasing since the early 2000s. However, an important limitation in the peer-reviewed literature is that CKD prevalence in more recent years has not been analyzed.

Researchers analyzed data from the national Health and Nutrition Examination Survey (NHANES) to estimate the trends in CKD prevalence overall and in subgroups of the population, with particular attention given to more recent years. They found that stage 3 and 4 CKD has not increased appreciably in the U.S. population overall during the most recent decade. The lack of increase was noted in most subgroups examined when data were stratified by age, sex, race/ethnicity, and diabetes status, except for among non-Hispanic black persons. The authors express concern over these findings and suggest further research to better understand potentially important differences in patterns by racial/ethnic subgroups. The research could help to inform strategies for improving CKD prevalence trends for all population groups.

Note: For an embargoed PDF, please contact Cara Graeff. The lead author, Dr. Chi-yuan Hsu, can be reached through Katherine "Leigh" Beeson at Katherine.Beeson@ucsf.edu.




3. Patients should weigh benefits and risks when medication to reduce breast cancer risk is recommended
Annals of Internal Medicine and Beth Israel Deaconess Medical Center go "Beyond the Guidelines" to discuss pharmacological interventions to reduce breast cancer risk
Free content: http://www.annals.org/article.aspx?doi=10.7326/M16-0940
URL goes live when the embargo lifts

Should a 51 year-old woman with a strong family history of breast cancer be offered medication to reduce her own breast cancer risk? An oncologist and an internist debate the topic in a multicomponent educational article being published in Annals of Internal Medicine.

Clinical guidelines from the U.S. Preventive Services Task Force recommend that physicians discuss treatment with selective estrogen receptor modulators (tamoxifen, raloxifene) with their postmenopausal patients that have an increased 5-year risk for breast cancer, as the benefits of treatment may outweigh the potential harms. Similarly, the American Society of Clinical Oncology recommends that women aged 35 years or older at increased risk for breast cancer discuss the use of preventative medications, including the aromatase inhibitor exemestane, which is not approved by the FDA for this purpose, with their primary care providers. In this Beyond the Guidelines article, an oncologist and a primary care physician debate whether or not to prescribe pharmacotherapy for a premenopausal patient who does not fit exactly within guideline parameters. Both physicians agree that shared decision making is essential and must include informing the patient of the specific benefits and risks associated with treatment.

All Beyond the Guidelines papers are based on the Department of Medicine Grand Rounds at Beth Israel Deaconess Medical Center in Boston. Each session focuses on care of a patient who "falls between the cracks" in available evidence and for whom the optimal clinical management is unclear. Such situations include those in which a guideline finds evidence insufficient to make a recommendation, a patient does not fit criteria mapped out in recommendations, or different organizations provide conflicting recommendations. Debates are presented in a question and answer format, and include video interviews with the patient and physicians. A list of topics is available at http://www.annals.org/grandrounds.

Note: For an embargoed PDF, please contact Cara Graeff. To interview the lead author, please contact Lizzie Williamson at erwillia@bidmc.harvard.edu or 617-632-8217.




Also in this issue:

Bioequivalence of Biosimilar Tumor Necrosis Factor-_ Inhibitors Compared With Their Reference Biologics: A Systematic Review and Meta-analysis
Francine Chingcuanco, MHS; Jodi Segal, MD, MPH; Seoyoung C. Kim, MD, ScD, MSCE; and G. Caleb Alexander, MD
Review
Abstract: http://www.annals.org/article.aspx?doi=10.7326/M16-0428

The Biosimilarity Concept: Toward an Integrated Framework for Evidence Assessment
Issam Zineh, PharmD, MPH; Leah A. Christl, PhD
Editorial
Abstract: http://www.annals.org/article.aspx?doi=10.7326/M16-1559

Annals Graphic Medicine - I'd Want a Natural Death
Nathan Gray, MD
Graphic Medicine
Free content: http://www.annals.org/article.aspx?doi=10.7326/G16-0002

Visceral Vistas: Basil Hirschowitz and the Birth of Fiberoptic Endoscopy
Ian S. Campbell, MD; Joel D. Howell, MD, PhD; and H. Hughes Evans, MD, PhD
History of Medicine
Abstract: http://www.annals.org/article.aspx?doi=10.7326/M16-0025
-end-


American College of Physicians

Related Breast Cancer Articles:

Does MRI plus mammography improve detection of new breast cancer after breast conservation therapy?
A new article published by JAMA Oncology compares outcomes for combined mammography and MRI or ultrasonography screenings for new breast cancers in women who have previously undergone breast conservation surgery and radiotherapy for breast cancer initially diagnosed at 50 or younger.
Blood test offers improved breast cancer detection tool to reduce use of breast biopsy
A Clinical Breast Cancer study demonstrates Videssa Breast can inform better next steps after abnormal mammogram results and potentially reduce biopsies up to 67 percent.
Surgery to remove unaffected breast in early breast cancer increases
The proportion of women in the United States undergoing surgery for early-stage breast cancer who have preventive mastectomy to remove the unaffected breast increased significantly in recent years, particularly among younger women, and varied substantially across states.
Breast cancer patients with dense breast tissue more likely to develop contralateral disease
Breast cancer patients with dense breast tissue have almost a two-fold increased risk of developing disease in the contralateral breast, according to new research from The University of Texas MD Anderson Cancer.
Some early breast cancer patients benefit more from breast conservation than from mastectomy
Breast conserving therapy (BCT) is better than mastectomy for patients with some types of early breast cancer, according to results from the largest study to date, presented at ECC2017.
One-third of breast cancer patients not getting appropriate breast imaging follow-up exam
An annual mammogram is recommended after treatment for breast cancer, but nearly one-third of women diagnosed with breast cancer aren't receiving this follow-up exam, according to new findings presented at the 2016 Annual Clinical Congress of the American College of Surgeons.
Low breast density worsens prognosis in breast cancer
Even though dense breast tissue is a risk factor for breast cancer, very low mammographic breast density is associated with a worse prognosis in breast cancer patients.
Is breast conserving therapy or mastectomy better for early breast cancer?
Young women with early breast cancer face a difficult choice about whether to opt for a mastectomy or breast conserving therapy (BCT).
Breast density and outcomes of supplemental breast cancer screening
In a study appearing in the April 26 issue of JAMA, Elizabeth A.
Full dose radiotherapy to whole breast may not be needed in early breast cancer
Five years after breast-conserving surgery, radiotherapy focused around the tumor bed is as good at preventing recurrence as irradiating the whole breast, with fewer side effects, researchers from the UK have found in the large IMPORT LOW trial.

Related Breast Cancer Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Anthropomorphic
Do animals grieve? Do they have language or consciousness? For a long time, scientists resisted the urge to look for human qualities in animals. This hour, TED speakers explore how that is changing. Guests include biological anthropologist Barbara King, dolphin researcher Denise Herzing, primatologist Frans de Waal, and ecologist Carl Safina.
Now Playing: Science for the People

#SB2 2019 Science Birthday Minisode: Mary Golda Ross
Our second annual Science Birthday is here, and this year we celebrate the wonderful Mary Golda Ross, born 9 August 1908. She died in 2008 at age 99, but left a lasting mark on the science of rocketry and space exploration as an early woman in engineering, and one of the first Native Americans in engineering. Join Rachelle and Bethany for this very special birthday minisode celebrating Mary and her achievements. Thanks to our Patreons who make this show possible! Read more about Mary G. Ross: Interview with Mary Ross on Lash Publications International, by Laurel Sheppard Meet Mary Golda...